Don't miss this crucial inflation read... 💲

Good Morning! Hey, there! It's Chris from Elite Trade Club, here to give you this morning's premarket trading news. Happy Friday! It's October 27th. I hope you have a great weekend. Now, let's get ready to trade! Markets 📈 Stocks continued their slump with more steep losses on Thursday. The Nasdaq sold off for 1.7%, alongside the S&P 500's 1.1% loss. The Dow lost 0.7%, and the small-cap Russell 2K managed to closed with a small 0.3% gain. S&P 500 futures are up 0.2% in early trading. It's anyone's guess which way the market will open today. Sponsored [[Free Copy] Hedge Fund Black Book]( Legendary hedge fund veteran David Prince's is generating a tremendous buzz. He recently put together a report that exposes the #1 weekly options strategy used by Wall Street's top firms. See how he tracks down his favorite stock of the week, how he selects the best option contract, and much more. [Get Started Here]( Premarket Highlights 🔎 🌞 The Clouds are Gathering for Solar Stocks Solar investors have a mean case of sunburn thanks to weaker-than-expected earnings results plaguing the sector this quarter. In the latest edition of the solar sector's struggle session, Enphase Energy [ENPH] dropped a projection bomb, signaling revenue expectations for the upcoming quarter are nowhere near what Wall Street was expecting. The Numbers Speak 📊 In pre-market maneuvers, Enphase's stock plunged over 21%, dragging it down to about $75.50—its lowest in more than three years. Ouch. This follows an already grim scenario: the stock had plummeted 64% this year alone. Ripple Effects 🌊 Enphase's bad news didn't stop at its own doorstep. Fellow solar companies SunRun [RUN] and SolarEdge [SEDG] saw their shares slip, too. SolarEdge is also having a rough year. Its shares are down by a staggering 70% this year, and it just suffered a big pullback a few weeks ago. The Bigger Picture 🌍 So, what's cooking in the clean energy sector? Well, it's not all sunshine and rainbows. Solar stocks have been wrestling with headwinds like rising interest rates, supply-chain fiascos, and other issues. Germany's Siemens Energy, which plays in the wind-power sandbox, dropped 33% Thursday after seeking financial backing from the German government and banks. The Bottom Line 🏁 Enphase's stock slide is the latest cautionary tale in an industry that's currently facing its share of challenges. Whether this is a temporary cloud cover or the onset of a longer winter for clean energy investments remains to be seen. So, if you're a solar bull, keep that umbrella handy because there could be many more storms to weather before the sun shines on the sector again. What to Watch Today 👀 Crucial Inflation Read The PCE Index is the Federal Reserve's preferred gauge for measuring inflation, and we'll get a fresh helping of new data this morning. In August, the PCE index, or personal consumption expenditures index, showed prices inflated at a 3.5% clip compared to a year ago. The market is looking for a lower figure in today's report, and sentiment could become very bearish if the report shows an unexpected increase in inflation compared to the previous month. Major Earnings 💰 ExxonMobil Corporation [XOM] ... AM Chevron Corporation [CVX] ... AM AbbVie [ABBV] ... AM AON PLC [AON] ... AM Charter Communications [CHTR] ... AM Colgate-Palmolive Company [CL] ... AM Phillips 66 [PSX] ... AM Xcel Energy [XEL] ... AM LyondellBasell Industries NV [LYB] ... AM T. Rowe Price Group [TROW] ... AM Economy 🏗 - Personal spending [Sep] ... 8:30a - PCE index [Sep] ... 8:30a - Consumer sentiment (final) [Oct] ... 10:00a Running Hot 🔥 Gainers - Sea Star Medical [ICU] >> +36.3% - ABVC Biopharma [ABVC] >> +23.4% - Rail Vision Unit [RVSN] >> +20.8% Decliners - Benson Hill [BHIL] >> (27.9%) - PTC Therapeutics [PTCT] >> (22.7%) - Sanofi ADR [SNY] >> (16.2%) DexCom [DXCM] - Last Close: $81.09 A blockbuster quarterly report is lifting shares of DexCom. The healthcare equipment stock reported its Q3 results Thursday evening, and the results blew the market away. DexCom generated EPS of $0.50, nearly doubling last year's Q3 earnings $0.28 per share, and easily topped Wall Street's $0.33 consensus. Revenues jumped 26.6% year-on-year to $975.0 million, which also crushed analysts' estimate of $937.6 million. The company also boosted its full-year revenue outlook, and announced the launch of a $500 million share buyback plan. DXCM is the leading large-cap in today's premarket with a 16.5% gain. My Take: DXCM shares have suffered a jaw-dropping pullback since August, so that's why its reacting so strongly to this news. It looks like this news may help the stock pivot to a new positive trend. Possible swing trade opportunity. NKGen Biotech [NKGN] - Last Close: $3.78 New drug data is giving NKGen Bio a big boost. The drugmaker presented new Phase 1 clinical trial data for its SNK01 drug candidate for Alzheimer's patients at an industry conference in Boston. NKGen said the drug produced notable improvements in patients, with zero subjects experiencing treatment-related adverse events. Company reps said the trial will likely clear the way for a U.S. IND clearance for a Phase I/IIa study in patients with moderate stage Alzheimer's. NKGN is up 22.4% on active premarket trading volume. My Take: NKGN has been shooting higher over the past few sessions, but there's still plenty of potential upside on the stable. Just last month, shares were trading for over $10. If this drug continues to show promise, this tiny biotech could be a compelling trading candidate. Apollomics [APLM] - Last Close: $0.5680 Apollomics is trading wildly in the week of a recent announcement. Yesterday morning, the company said its PTPRZ-MET fusion treatment produced an impressive partial response in a SPARTA study. After 8 weeks of treatment, a brain tumor patient treated with vebreltinib monotherapy exhibited the aforementioned partial response. Apollomics' CEO said the data demonstrates “the potential of vebreltinib as a new treatment for patients with cancers driven by MET alterations.” APLM suffered a 26.2% decline on Thursday following this press release, but shares are up 105.9% in today's premarket. My Take: This data seems promising, so I'm not sure why APLM sold off yesterday. It's suffered big losses in recent months, so this big rally could be exaggerated as the result of being oversold. BIO-Key [BKYI] - Last Close: $0.1707 BIO-Key is surging after announcing a new contract. The tiny company announced a new secure data access deal with logistics provider ALPI Portugal. Under the deal, ALPI Portugal will implement multifactor authentication and SSO to protect internal users, third party drivers, and users of their B2B website. According to a company rep, BIO-Key now has over 1 million seat licenses outstanding in the critical logistics sector with the signing of this deal. Financial details of the arrangement weren't disclosed, but shares of BIO-Key are surging on the news. BKYI is one of this morning's top stocks with a 140.1% gain. My Take: BKYI is also coming off a big pullback, and it's a very, VERY small float stock with a market cap of only $1.61 million. There could be lots of short-term opportunities here, but buckle up and prepare for volatility if you want to dabble. That's it for today! Thanks for reading, and good luck out there! Best Regards, Chris D. -- Elite Trade Club P.S... Want alerts delivered straight to your cell every morning for free?* Text ELITE to 47121 to sign up now and get our watchlists sent directly to your phone! Or text CLOSE to 47121 to get on the mobile alert list for our Closing Bell Roundup report, featuring the day's top winners and losers. *Standard message/carrier rates may apply. Legal Stuff: Stocks featured in this newsletter are for entertainment purposes only. You should not base any investment decisions on information contained in my newsletter. Stocks featured in this newsletter may be owned by owners/operators of this website which could impact our ability to remain unbiased. Please consult a financial advisor before making any trading decisions. I may earn a small commission from links placed inside of these emails. [Bots click here]( 1969 S. ALAFAYA TRAIL Orlando FL 32828 USA [Unsubscribe]( | [Change Subscriber Options](